DMD Development Landscape Shifts After Prosensa Failure; Sarepta Continues Strong
Executive Summary
The race to get a Duchenne muscular dystrophy drug to market has been closely watched by investors; new developments in drugs by Prosensa and Sarepta have created an unexpected change in the landscape of treatment development.